Cartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform

Dow Jones

Jun 09

By Adriano Marchese

Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis.

Shares traded 25% higher ahead of the morning bell at $7.35.

The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases.

The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year.

The company also said the partnership provides a framework to move additional programs into human testing more efficiently.

Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 09, 2026 08:59 ET (12:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2642498856"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642498856\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642498856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642498856","market":"sh","top_or_hot":-1,"title":"Cartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis. \n</p>\n<p>\n  Shares traded 25% higher ahead of the morning bell at $7.35. \n</p>\n<p>\n  The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases. \n</p>\n<p>\n  The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year. \n</p>\n<p>\n  The company also said the partnership provides a framework to move additional programs into human testing more efficiently. \n</p>\n<p>\n  Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 08:59 ET (12:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-09 20:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis. \n</p>\n<p>\n  Shares traded 25% higher ahead of the morning bell at $7.35. \n</p>\n<p>\n  The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases. \n</p>\n<p>\n  The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year. \n</p>\n<p>\n  The company also said the partnership provides a framework to move additional programs into human testing more efficiently. \n</p>\n<p>\n  Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 08:59 ET (12:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNAC","symbol_name":"Cartesian Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642498856","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642498856","pubTimestamp":1781009940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis.Shares traded 25% higher ahead of the morning bell at $7.35.The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases.The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year.The company also said the partnership provides a framework to move additional programs into human testing more efficiently.Under the terms of the agreement, WestGene will rec","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RNAC":"Cartesian Therapeutics","BK4139":"生物科技"},"translate_title":"Cartesian Therapeutics股价因WestGene递送平台许可协议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAC":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis. \n\n\n  Shares traded 25% higher ahead of the morning bell at $7.35. \n\n\n  The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases. \n\n\n  The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year. \n\n\n  The company also said the partnership provides a framework to move additional programs into human testing more efficiently. \n\n\n  Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 08:59 ET (12:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}